FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2070290142> ?p ?o ?g. }

• W2070290142 endingPage "93" @default.
• W2070290142 startingPage "75" @default.
• W2070290142 abstract "Journal of Clinical Pharmacy and TherapeuticsVolume 11, Issue 2 p. 75-93 Free Access RECENT ADVANCES IN PHARMACEUTICAL CHEMISTRY:THE 4-QUINOLONE ANTIBIOTICS D.B. Jack, D.B. Jack Department of Therapeutics and Clinical Pharmacology, Medical School, University of Birmingham, Birmingham B15 2TJ, U.K.Search for more papers by this author D.B. Jack, D.B. Jack Department of Therapeutics and Clinical Pharmacology, Medical School, University of Birmingham, Birmingham B15 2TJ, U.K.Search for more papers by this author First published: April 1986 https://doi.org/10.1111/j.1365-2710.1986.tb00831.xCitations: 3AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES 1 Smith, J.T. (1984) Awakening the slumbering potential of the 4-quinolone antibacterials. Pharmaceutical Journal, 233, 299– 305. 2 Lesher, G.Y., Froehlich, E.J., Gruett, M.D., Bailey, J.H. & Brundage, R.P. (1962) 1,8 Naphthyridine derivatives. Journal of Medicinal Chemistry, 5, 1063– 1065. 3 Gleckman, R., Alvarez, S., Joubert, D.W. & Mathhews, S.J. (1979) Drug therapy reviews: nalidixic acid. American Journal of Hospital Pharmacy, 36, 1071– 1076. 4 Schentag, J.T. & Domagala, J.M. (1985) Structure-activity relationships with the quinoline antibiotics. Research and Clinical Forums, 7, 9– 15. 5 Albrecht, R. (1977) Development of antibacterial agents of the nalidixic acid type. In: Progress in Drug Research, 21, 9– 104, Karger, Basle . 6 Smith, J.T. (1984) Chemistry and mode of action of 4-quinolone agents. Fortschritte der antimikrobiellen und antineoplastischen Chemotherapie, Band, 3–5, 493– 508. 7 Kayser, F.H. (1985) The quinolones: mode of action and mechanism of resistance. Research and Clinical Forums, 7, 17– 27. 8 Jack, D.B., Hawker, J.I., Patel, P., Rooney, L., Lobo, J., Fuentes, J. & Laugher, S.J. (1985) The rapid measurement of drug distribution coefficients using thin-layer chromatography. 45th International Congress of Pharmaceutical Sciences, Montreal, abstract 24. 9 Montay, G., Goueffon, Y. & Roquet, F. (1984) Absorption, distribution, metabolism and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys and humans. Antimicrobial Agents and Chemotherapy, 25, 463– 472. 10 Wise, R., Lockley, R.M., Webberly, M. & Dent, J. (1984) Pharmacokinetics of intravenously administered ciprofloxacin. Antimicrobial Agents and Chemotherapy, 26, 208– 210. 11 Beerman, D. (1984) Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. European Journal of Clinical Microbiology, 3, 355– 359. 12 Gau, W., Ploschke, H.J., Schmidt, K. & Weber, B. (1985) Determination of ciprofloxacin (BAY o 9867) in biological fluids by high-performance liquid chromatography. Journal of Liquid Chromatography, 8, 485– 497. 13 Vree, T.B., Baars, A.M. & Wijnands, W.J.A. (1985) High-performance liquid chromatography and preliminary pharmacokinetics of enoxacin and its 4-oxo metabolite in human plasma, urine and saliva. Journal of Chromatography, 343, 449– 454. 14 Kullberg, M.P., Koss, R., O'Neil, S. & Edelson, J. (1979) High-performance liquid chromatographic analysis of rosoxacin and its N-oxide metabolite in plasma and urine. Journal of Chromatography, 173, 155– 163. 15 Nakamura, R., Yamaguchi, T., Sekine, Y. & Hashimoto, M. (1983) Determination of a new antibacterial agent (AT-2266) and its metabolites in plasma and urine by high-performance liquid chromatography. Journal of Chromatography, 278, 321– 328. 16 Gutzler, F. & de Vries, J.X. (1984) Bestimmung von Norfloxacin in Plasma und Urin durch Hochdruckflüssigkeitschromatographie. Fortschritte der antimikrobiellen und antineoplastischen Chemotherapie, Band 3–5, 673– 677. 17 Dagrosa, E., Seeger, K., Malerczyk, V. & Lameire, N. (1984) Pharmakokinetik von Ofloxacin (HOE 280). Fortschritte der antimikrobiellen und neoplastischen Chemotherapie, Band 3–5, 665– 671. 18 Höffken, G., Lode, H., Prinzing, C., Borner, K. & Koeppe, O. (1985) Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrobial Agents and Chemotherapy, 27, 375– 379. 19 Nelson, J.D., Shelton, S., Kusmiesz, H.T. & Haltalin, K.C. (1972) Absorption of ampicillin and nalidixic acid by infants and children with acute shigellosis. Clinical Pharmacology and Therapeutics, 13, 879– 886. 20 Ball, P., Fox, C. & Ball, M. (1985) Fasting vs. non-fasting pharmacokinetics of ciprofloxacin in young volunteers and elderly patients. In: Ciprofloxacin U.K. Workshops, 1985. pp. 52– 53. Bayer U.K. Ltd. 21 Swanson, B.N., Boppana, V.K., Vlasses, P.H. Rotmensch, H.H. & Ferguson, R.K. (1983) Norfloxacin disposition after sequentially increasing oral doses. Antimicrobial Agents and Chemotherapy, 23, 284– 288. 22 Dalhoff, A. & Weidner, W. (1984) Diffusion of ciprofloxacin into prostatic fluid. European Journal of Clinical Microbiology, 3, 360– 362. 23 Adhami, Z.N., Wise, R., Weston, D. & Crump, B. (1984) The pharmacokinetics and tissue penetration of norfloxacin. Journal of Antimicrobial Chemotherapy, 13, 87– 92. 24 Maigaard, S., Frimodt-Möller, N., Hoyme, U. & Madsen, P.O. (1979) Rosoxacin and cinoxacin distribution in prostate, vagina and female urethra. Investigative Urology, 17, 149– 152. 25 Ito, Y., Fujimoto, Y., Hasegawa, Y., Kato, N., Kawada, Y. & Nishiura, T. (1984) Prostatic tissue levels of DL-8280. Chemotherapy, 32, S-1, 669– 672. 26 Jameson, R.M. (1965) Tissue concentrations of nalidixic acid in chronic pyelonephritis. British Medical Journal, 2, 621– 623. 27 Boppana, V.K. & Swanson, B.N. (1982) Determination of norfloxacin, a new nalidixic acid analog in human serum and urine by high-pressure liquid chromatography. Antimicrobial Agents and Chemotherapy, 21, 808– 810. 28 Edelson, J., Davison, C. & Benziger, D.P. (1977) Quinolone and ‘Azaquinolone’ antimicrobial agents. Drug Metabolism Reviews, 6, 105– 148. 29 Bolaert, J., Valcke, Y., Schurgers, M., Daneels, R., Rosseneu, M., Rosseel, M.T. & Bogaert, M.G. (1985) The pharmacokinetics of ciprofloxacin in patients with impaired renal function. Journal of Antimicrobial Chemotherapy, 16, 87– 93. 30 Arrigo, G., Cavaliere, G., D'Amico, G., Passarella, E. & Broccali, G. (1985) Pharmacokinetics of norfloxacin in chronic renal failure. International Journal of Clinical Pharmacology, Therapy and Toxicology, 23, 491– 496. 31 Roquet, F. (1984) Elimination biliaire. In: Péflacine, p. 72. Laboratoire Roger Bellon, France . 32 Neuman, M., Charbonnier, A. & Cachin, M. (1967) Proceedings of the 5th International Congress of Chemotherapy, pp. 327– 332, Vienna . 33 Tweedle, D.E.F., Manson, J. McK. & Ball, C.S. (1985) Excretion of ciprofloxacin in bile. In: Ciprofloxacin U.K. Workshops 1985, pp. 71– 75, Bayer U.K. Ltd. 34 Young, L.S. (1985) Clinical experience with newer quinolones. Research and Clinical Forums, 7, 97– 114. 35 Schacht, P., Bruck, H., Chysky, V., Hullman, R., Wenta, H., Arcieri, G., Branolte, J., Konopka, C., Papachristian, C. & Westwood, A. (1985) Overall clinical results with ciprofloxacin. In: Ciprofloxacin U.K. Workshops 1985, pp. 134– 136, Bayer U.K. Ltd. 36 Arcieri, G. (1985) Summary of U.S. clinical experience with ciprofloxacin. In: Ciprofloxacin U.K. Workshops 1985, p. 133, Bayer U.K. Ltd. 37 Wijnands, W.J.A., van Herwaarden, C.L.A. & Vree, T.B. (1984) Enoxacin raises plasma theophylline concentration. Lancet, ii, 108– 109. 38 Weber, A., Chaffin, D., Smith, A. & Opheim, K.E. (1985) Quantitation of ciprofloxacin in body fluids by high-performance liquid chromatography. Antimicrobial Agents and Chemotherapy, 27, 531– 534. 39 Wingender, W., Graefe, K.-H., Gau, W., Förster, D., Beermann, D. & Schacht, P. (1984) Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. European Journal of Clinical Microbiology, 3, 355– 359. 40 Montay, G., Blain, Y., Roquet, F. & Le Hir, A. (1983) High-performance liquid chromatography of pefloxacin and its main active metabolites in biological fluids. Journal of Chromatography, 272, 359– 365. 41 Ichihara, N. (1984) Phase I study of DL-8280. Chemotherapy, 32, S-1, 119– 148. 42 Shargel, L., Koss, R.F., Crain, A.V.R. & Boyle, V.J. (1973) Nalidixic acid and hydroxynalidixic acid analysis in human plasma and urine by liquid chromatography. Journal of Pharmaceutical Sciences, 62, 1452– 1454. 43 Perényi, T. (1975) A nalidixsav humán biotranszformációja. Acta Pharmaceutica Hungarica, 45, 196– 206. 44 Zio, C.A., Massarani, G. & Pietta, P. (1980) Estimation of pipemidic acid and N-nitroso-pipemidic acid by high-performance liquid chromatography, Journal of Chromatography, 200, 245– 249. 45 Kurobe, N., Nakamura, S. & Shimizu, M. (1980) Metabolites of pipemidic acid in human urine. Xenobiotica, 10, 37– 46. 46 Harrison, L.I., Schuppan, D., Rohlfing, S.R., Hansen, A.R. Hansen, C.S., Funk, M.L., Collins, S.H. & Ober, R.E. (1984) Determination of flumequine and a hydroxymetabolite in biological fluids by high-pressure liquid chromatography, fluorometric and microbiological methods. Antimicrobial Agents and Chemotherapy, 25, 301– 305. Citing Literature Volume11, Issue2April 1986Pages 75-93 ReferencesRelatedInformation" @default.
• W2070290142 created "2016-06-24" @default.
• W2070290142 creator A5075953479 @default.
• W2070290142 date "1986-04-01" @default.
• W2070290142 modified "2023-09-24" @default.
• W2070290142 title "RECENT ADVANCES IN PHARMACEUTICAL CHEMISTRY:THE 4-QUINOLONE ANTIBIOTICS" @default.
• W2070290142 cites W1966022758 @default.
• W2070290142 cites W1976300913 @default.
• W2070290142 cites W1985968809 @default.
• W2070290142 cites W2002118624 @default.
• W2070290142 cites W2011422043 @default.
• W2070290142 cites W2021188463 @default.
• W2070290142 cites W2024544523 @default.
• W2070290142 cites W2032567576 @default.
• W2070290142 cites W2033213467 @default.
• W2070290142 cites W2040781990 @default.
• W2070290142 cites W2047269151 @default.
• W2070290142 cites W2066926259 @default.
• W2070290142 cites W2067077819 @default.
• W2070290142 cites W2067469709 @default.
• W2070290142 cites W2070749982 @default.
• W2070290142 cites W2080306383 @default.
• W2070290142 cites W2115431161 @default.
• W2070290142 cites W2128871366 @default.
• W2070290142 cites W2141265083 @default.
• W2070290142 cites W2145580778 @default.
• W2070290142 cites W2170592342 @default.
• W2070290142 cites W2318091958 @default.
• W2070290142 cites W2408081130 @default.
• W2070290142 cites W4366064567 @default.
• W2070290142 doi "https://doi.org/10.1111/j.1365-2710.1986.tb00831.x" @default.
• W2070290142 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3519688" @default.
• W2070290142 hasPublicationYear "1986" @default.
• W2070290142 type Work @default.
• W2070290142 sameAs 2070290142 @default.
• W2070290142 citedByCount "7" @default.
• W2070290142 crossrefType "journal-article" @default.
• W2070290142 hasAuthorship W2070290142A5075953479 @default.
• W2070290142 hasBestOaLocation W20702901421 @default.
• W2070290142 hasConcept C178855305 @default.
• W2070290142 hasConcept C185592680 @default.
• W2070290142 hasConcept C21951064 @default.
• W2070290142 hasConcept C2779922871 @default.
• W2070290142 hasConcept C501593827 @default.
• W2070290142 hasConcept C55493867 @default.
• W2070290142 hasConcept C71924100 @default.
• W2070290142 hasConcept C98274493 @default.
• W2070290142 hasConceptScore W2070290142C178855305 @default.
• W2070290142 hasConceptScore W2070290142C185592680 @default.
• W2070290142 hasConceptScore W2070290142C21951064 @default.
• W2070290142 hasConceptScore W2070290142C2779922871 @default.
• W2070290142 hasConceptScore W2070290142C501593827 @default.
• W2070290142 hasConceptScore W2070290142C55493867 @default.
• W2070290142 hasConceptScore W2070290142C71924100 @default.
• W2070290142 hasConceptScore W2070290142C98274493 @default.
• W2070290142 hasIssue "2" @default.
• W2070290142 hasLocation W20702901421 @default.
• W2070290142 hasLocation W20702901422 @default.
• W2070290142 hasOpenAccess W2070290142 @default.
• W2070290142 hasPrimaryLocation W20702901421 @default.
• W2070290142 hasRelatedWork W1540951779 @default.
• W2070290142 hasRelatedWork W1985319380 @default.
• W2070290142 hasRelatedWork W1997784689 @default.
• W2070290142 hasRelatedWork W2010901802 @default.
• W2070290142 hasRelatedWork W2319299144 @default.
• W2070290142 hasRelatedWork W2413857775 @default.
• W2070290142 hasRelatedWork W3013167941 @default.
• W2070290142 hasRelatedWork W4244363685 @default.
• W2070290142 hasRelatedWork W4254598222 @default.
• W2070290142 hasRelatedWork W4319924575 @default.
• W2070290142 hasVolume "11" @default.
• W2070290142 isParatext "false" @default.
• W2070290142 isRetracted "false" @default.
• W2070290142 magId "2070290142" @default.
• W2070290142 workType "article" @default.